The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phage-antibiotic combinations to control Pseudomonas aeruginosa–Candida two-species biofilms
Published version of a preprint
Abstract
Phage-antibiotic combinations to treat bacterial infections are gaining increased attention due to the synergistic effects often observed when applying both components together. Most studies however focus on a single pathogen, although in many clinical cases multiple species are present at the site of infection. The aim of this study was to investigate the anti-biofilm activity of phage-antibiotic/antifungal combinations on single- and dual-species biofilms formed by P. aeruginosa and the fungal pathogen Candida albicans . The Pseudomonas phage Motto in combination with ciprofloxacin had significant anti-biofilm activity. We then compared biofilms formed by P. aeruginosa alone with the dual-species biofilms formed by bacteria and C. albicans . Here, we found that the phage together with the antifungal fluconazole was active against 6-h-old dual-species biofilms but showed only negligible activity against 24-h-old biofilms. This study lays the first foundation for potential therapeutic approaches to treat co-infections caused by bacteria and fungi using phage-antibiotic combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phage antibiotic combinations often outperform either alone.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [214]
In the citing paper
“In vitro and in vivo models that include zebrafish and murine airway and implant systems show accelerated clearance and improved survival, with reduced emergence of resistance [213,214,215].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [214]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Pseudomonas aeruginosa quorum‐sensing molecule influences Candida albicans morphology
Hogan, D. A., Vik, Å., & Kolter, R. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04349.x · Cited by 575
In vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.
Hotterbeekx, A., Kumar-Singh, S., Goossens, H., & Malhotra-Kumar, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00106 · Cited by 289
Manohar, P., Shanthini, T., Ayyanar, R., Bozdogan, B., Wilson, A., Tamhankar, A. J., Nachimuthu, R., & Lopes, B. S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000508 · Cited by 104
Self-citation
Research works printed but not linked: 35
- Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 25, 219–232 (2019). · DOI · Paper page
- Luong, T., Salabarria, A. C. & Roach, D. R. Phage therapy in the resistance era: Where do we stand and where are we going?. Clin. Ther. 42, 1659–1680 (2020). · DOI · Paper page
- Segall, A. M., Roach, D. R. & Strathdee, S. A. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr. Opin. Microbiol. 51, 46–50 (2019). · DOI
- Gu Liu, C. et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio 11, e01462-e1520 (2020). · DOI · Paper page
- Uchiyama, J. et al. Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa. Arch. Virol. 163, 1941–1948 (2018). · doi:10.1007/s00705-018-3811-0
- Manohar, P. et al. Synergistic effects of phage-antibiotic combinations against Citrobacter amalonaticus. ACS Infect. Dis. 8, 59–65 (2022). · DOI
- Gordillo Altamirano, F. et al. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat. Microbiol. 6, 157–161 (2021). · DOI · Paper page
- Wang, X., Loh, B., Yu, Y., Hua, X. & Leptihn, S. Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture. Emerg. Microbes Infect. 10, 2205–2219 (2021). · DOI
- Engeman, E. et al. Synergistic Killing and re-sensitization of Pseudomonas aeruginosa to antibiotics by phage-antibiotic combination treatment. Pharmaceuticals 14, 184 (2021). · DOI
- Mah, T. F. et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426, 306–310 (2003). · DOI · Paper page
- Oliveira, V. C. et al. Identification and characterization of new bacteriophages to control multidrug-resistant Pseudomonas aeruginosa biofilm on endotracheal tubes. Front. Microbiol. 11, 580779 (2020). · DOI
- Chegini, Z. et al. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review. Ann. Clin. Microbiol. Antimicrob. 19, 1–7 (2020). · DOI · Paper page
- Akturk, E. et al. Synergistic action of phage and antibiotics: Parameters to enhance the killing efficacy against mono and dual-species biofilms. Antibiotics 8, 103 (2019). · DOI · Paper page
- Chang, R. Y. et al. Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients. AAPS J. 21, 49 (2019). · DOI
- Kasetty, S., Mould, D. L., Hogan, D. A. & Nadell, C. D. Both Pseudomonas aeruginosa and Candida albicans accumulate greater biomass in dual-species biofilms under flow. mSphere 6, e00416-e421 (2021). · DOI
- Hogan, D. A. & Kolter, R. Pseudomonas-Candida interactions: An ecological role for virulence factors. Science 296, 2229–2232 (2002). · DOI · Paper page
- Carolus, H., Van Dyck, K. & Van Dijck, P. Candida albicans and Staphylococcus species: A threatening twosome. Front. Microbiol. 10, 2162 (2019). · DOI · Paper page
- Bandara, H. M., Yau, J. Y., Watt, R. M., Jin, L. J. & Samaranayake, L. Pseudomonas aeruginosa inhibits in-vitro Candida biofilm development. BMC Microbiol. 10, 125 (2010). · DOI
- Morales, D. K. et al. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. MBio 4, e00526-e612 (2013). · DOI · Paper page
- Manohar, P. et al. Complete Genome Sequence of Pseudomonas Phage Motto. Microbiol. Resour. Announc. 11, e00740-e822 (2022). · doi:10.1128/mra.00740-22
- Manohar, P., Loh, B., Turner, D., Tamizhselvi, R., Mathankumar, M., Elangovan, N., Nachimuthu, R. & Leptihn, S. In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy. Front. Microbial. 15, 344962 (2024).
- Sharma, D., Misba, L. & Khan, A. U. Antibiotics versus biofilm: An emerging battleground in microbial communities. Antimicrob. Resist. Infect. Control 8(1), 1 (2019). · DOI · Paper page
- Azeredo, J., García, P. & Drulis-Kawa, Z. Targeting biofilms using phages and their enzymes. Curr. Opin. Biotechnol. 68, 251–261 (2021). · DOI
- Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 19, 35–45 (2019). · DOI · Paper page
- Altamirano, F. L. et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine 80, 104045 (2022). · DOI · Paper page
- Aghaee, B. L., Khan Mirzaei, M., Alikhani, M. Y., Mojtahedi, A. & Maurice, C. F. Improving the inhibitory effect of phages against Pseudomonas aeruginosa isolated from a burn patient using a combination of phages and antibiotics. Viruses 13, 334 (2021). · DOI
- Kebriaei, R. et al. Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination. Microbiol. Spectr. 10, e00411-e422 (2022). · doi:10.1128/spectrum.00411-22
- Grygorcewicz, B. et al. Environmental phage-based cocktail and antibiotic combination effects on Acinetobacter baumannii biofilm in a human urine model. Microb. Drug Resist. 27, 25–35 (2021). · doi:10.1089/mdr.2020.0083
- Ferry, T. et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat. Commun. 13, 4239 (2022). · doi:10.1038/s41467-022-31837-9
- Chang, R. Y. et al. The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clin. Microbiol. Infect. 28, 983–989 (2022). · DOI
- Leclair, L. W. & Hogan, D. A. Mixed bacterial-fungal infections in the CF respiratory tract. Med. Mycol. 48(Supplement_1), S125–S132 (2010). · DOI
- O’Brien, S. & Fothergill, J. L. The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung. FEMS Microbiol. Lett. 364, fnx128 (2017).
- Alam, F., Catlow, D., Di Maio, A., Blair, J. M. & Hall, R. A. Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm. J. Antimicrob. Chemother. 75, 925–935 (2020). · DOI
- Roszak, M. et al. Bacteriophage–ciprofloxacin combination effectiveness depends on Staphylococcus aureus–Candida albicans dual-species communities’ growth model. Microb. Drug Resist. 28(6), 613–622 (2022). · DOI
- Łusiak-Szelachowska, M. et al. Bacteriophages and antibiotic interactions in clinical practice: What we have learned so far. J. Biomed. Sci. 29, 1–7 (2022). · DOI · Paper page
Cited by
Current and future directions in bacteriophage research for developing therapeutic innovations
Cui, L., Kiga, K., Kondabagil, K., & Węgrzyn, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-76427-5 · Cited by 36
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Manohar, P., Loh, B., Nachimuthu, R., & Leptihn, S.
- Venue
- Scientific Reports
- Published
- 2024-04-23
- Volume
- 14
- Issue
- 1
- ISSN
- 2045-2322
- Cited by
- 55
- References
- 3
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- HMU Health and Medical University Erfurt GmbH
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage-antibiotic combinations to control Pseudomonas aeruginosa–Candida two-species biofilms. https://app.cochat.ai/papers/10.1038/s41598-024-59444-2
- The paper
- Manohar, P., Loh, B., Nachimuthu, R., & Leptihn, S. (2024). Phage-antibiotic combinations to control Pseudomonas aeruginosa–Candida two-species biofilms. Scientific Reports. https://doi.org/10.1038/s41598-024-59444-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.